SCHEMBL4918798

SCHEMBL4918798

COc1ccc(CNc2nc3ccc(Cl)cc3nc2OC)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 15/20 0.47
CYP3A4 P08684 15/20 0.47
CYP2C19 P33261 15/20 0.47
CYP2D6 P10635 14/20 0.47
TSHR P16473 13/20 0.47
CYP2C9 P11712 11/20 0.47
HSD17B10 Q99714 10/20 0.47
ALDH1A1 P00352 10/20 0.47
LMNA P02545 10/20 0.47
MAPT P10636 4/20 0.47
HIF1A Q16665 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
CLK4 Q9HAZ1 7/20 0.47
USP2 O75604 6/20 0.47
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
ALOX15 P16050 3/20 0.47
APLNR P35414 1/20 0.47
DHFR P00374 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4923082 0.92 APLNR (0.52) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL4925226 0.87 CYP1A2 (0.48) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL4925489 0.86 CYP1A2 (0.53) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL30908447 0.73 CYP1A2 (0.48) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL30908144 0.73 CYP1A2 (0.48) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL30498290 0.72 CYP1A2 (0.57) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL27199339 0.72 CYP1A2 (0.57) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL23852696 0.72 APLNR (0.59) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL18062214 0.72 APLNR (0.59) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL7350739 0.72 HRH4 (0.50) HSD17B10ALDH1A1LMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598173-B2 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives for treating tumors KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2013-12-03 US disclosed
US-20130053390-A1 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES REXAHN PHARMACEUTICALS, INC. 2013-02-28 US disclosed
US-8314100-B2 1-[6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives REXAHN PHARMACEUTICALS, INC. (US) 2012-11-20 US disclosed
US-20080318963-A1 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives REXAHN PHARMACEUTICALS, INC. (US) 2008-12-25 US disclosed
EP-1819698-A1 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES Rexahn Pharmaceuticals, Inc. (US) 2007-08-22 EP disclosed
WO-2006054830-A1 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES REXAHN PHARMACEUTICALS, INC. (US) 2006-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318963-A1 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives HRAS, CDK4, KRAS CYP1A2 896/4885CYP3A4 1237/4885CYP2C19 2977/4885
US-20130053390-A1 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES HRAS, CDK4, KRAS CYP1A2 668/4885CYP3A4 965/4885CYP2C19 2556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.